Tenosynovial giant cell tumors (TSGCT) are a group of neoplastic disorders that involve synovium-lined tendon sheaths, synovial joints, and adjacent soft tissue. These are locally aggressive, soft tissue lesions characterized by inflammation of the synovial lining among joints and tendons. These neoplasms are thought to arise via overexpression of the colony-stimulating factor 1 receptor. TSGCTs are also known as giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumor of the tendon sheath (PVNTS), extra-articular pigmented villonodular tumor of the tendon sheath, or localized or focal nodular synovitis.
These tumors are often classified by their growth pattern (localized or diffused) and location (intra- or extra-articular. When the tumor involves the tendons that support the joint or occurs in just one area of the joint, it is called localized PVNS. It is a rare, benign proliferating disorder of the synovium that can be locally aggressive affecting the joints, tendon sheaths, and bursa. Diffuse PVNS presented clinically as chronic mono-arthritis, commonly with hemarthrosis.
- The total diagnosed incident population of Tenosynovial Giant Cell Tumors (TSGCTs) in the seven major markets was found to be 13,580 cases in 2017.
- Among the EU5 countries, Germany had the maximum diagnosed incident population of TSGCTs i.e., 953 cases followed by the United Kingdom with 726 cases in 2017. While the lowest number of cases were found in Spain with 551 cases in 2017.
- Japan accounted for 2,346 cases of diagnosed Tenosynovial Giant Cell Tumors (TSGCTs) in 2017, which is expected to increase in the forecast period 2021–2030.
DelveInsight's "Tenosynovial Giant Cell Tumors (TSGCTs) Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Tenosynovial Giant Cell Tumors (TSGCTs) market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The report also covers emerging drugs, current treatment practices, Tenosynovial Giant Cell Tumors (TSGCTs) market shares of the individual therapies, a detailed current Tenosynovial Giant Cell Tumors (TSGCTs) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
Tenosynovial Giant Cell Tumors (TSGCTs) Market Analysis
Tenosynovial Giant Cell Tumors (TSGCTs) Market Size in the 7MM was found to be USD 217.65 Million in 2017.
The market size of Tenosynovial Giant Cell Tumors (TSGCTs) is expected to grow during the forecast period owing to the launch of upcoming therapies in the 7MM. Increasing awareness and changing lifestyles will also drive market growth.
The Tenosynovial Giant Cell Tumors (TSGCTs) market analysis section of the report helps to understand the current and forecasted Tenosynovial Giant Cell Tumors (TSGCTs) market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers.
The report gives complete detail of Tenosynovial Giant Cell Tumors (TSGCTs) market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Tenosynovial Giant Cell Tumors (TSGCTs) pipeline possesses potential drugs in late and mid-stage developments to be launched in the near future. Some of the key Tenosynovial Giant Cell Tumors (TSGCTs) Companies Novartis, AmMax Bio, Daiichi Sankyo, Five Prime Therapeutics, Deciphera Pharmaceuticals, and many others. Tenosynovial Giant Cell Tumors (TSGCTs) Therapies covered in the report include Tasigna (also known as Nilotinib, AMN107), Lacnotuzumab (MCS-110), Cabiralizumab, AMB-05X, Vimseltinib (DCC-3014), and many more.
Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology Subtype Segmentation
- Diagnosed Incidence of Tenosynovial Giant Cell Tumors (TSGCTs)
- Growth Pattern-specific Diagnosed Incidence of Tenosynovial Giant Cell Tumor (TSGCTs)
- Gender-specific Diagnosed Incidence of Localized Tenosynovial Giant Cell Tumors (L-TSGCTs)
- Gender-specific Diagnosed Incidence of Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs)
- Tumor Localization of Localized Tenosynovial Giant Cell Tumor (L-TSGCTs)
- Tumor Localization of Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs)
Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology Forecast
The Tenosynovial Giant Cell Tumors (TSGCTs) epidemiology section covers insights about historical and current Tenosynovial Giant Cell Tumors (TSGCTs) patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
It helps to recognize the causes of current and forecasted Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
For more details, visit: Tenosynovial Giant Cell Tumors (TSGCTs) Market Share